NEW HAVEN, Conn.--CuraGen was granted a US patent for specific aspects of its PathCalling protein analysis technology. Specifically, the patent covers the use of the yeast two-hybrid system in an ultra high-throughput manner, which the company employs to identify protein-protein interactions across entire genomes.